Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

Crump, 2017, Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study, Blood, 130, 1800, 10.1182/blood-2017-03-769620 Brudno, 2018, Chimeric antigen receptor T-cell therapies for lymphoma, Nat Rev Clin Oncol, 15, 31, 10.1038/nrclinonc.2017.128 Locke, 2017, Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma, Mol Ther, 25, 285, 10.1016/j.ymthe.2016.10.020 Abramson, 2018, Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL, J Clin Oncol, 36 Borchmann P, Tam CS, Jäger U, et al. An updated analysis of Juliet, a global pivotal phase 2 trial of tisagenlecleucel in adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). 23rd Congress of the European Hematology Association; Stockholm, Sweden; June 14–17, 2018; S799. Schuster, 2017, Chimeric antigen receptor T Cells in refractory B-cell lymphomas, N Engl J Med, 377, 2545, 10.1056/NEJMoa1708566 Kochenderfer, 2009, Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor, J Immunother, 32, 689, 10.1097/CJI.0b013e3181ac6138 Kochenderfer, 2010, Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells, Blood, 116, 3875, 10.1182/blood-2010-01-265041 Roberts, 2018, Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL, Leuk Lymphoma, 59, 1785, 10.1080/10428194.2017.1387905 Neelapu, 2017, Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma, N Engl J Med, 377, 2531, 10.1056/NEJMoa1707447 2018 Kochenderfer, 2017, Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy, Mol Ther, 25, 2245, 10.1016/j.ymthe.2017.07.004 2008 Cheson, 2007, Revised response criteria for malignant lymphoma, J Clin Oncol, 25, 579, 10.1200/JCO.2006.09.2403 Brudno, 2016, Toxicities of chimeric antigen receptor T cells: recognition and management, Blood, 127, 3321, 10.1182/blood-2016-04-703751 Lee, 2014, Current concepts in the diagnosis and management of cytokine release syndrome, Blood, 124, 188, 10.1182/blood-2014-05-552729 2010 Neelapu, 2018, Reply to letter to the editor: CAR T-Cell therapy in large B-cell lymphoma, N Engl J Med, 378, 1065, 10.1056/NEJMc1800913 Lee, 2015, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancet, 385, 517, 10.1016/S0140-6736(14)61403-3 Maude, 2018, Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia, N Engl J Med, 378, 439, 10.1056/NEJMoa1709866 Chavez, 2017, A possible cure for refractory DLBCL: CARs are headed in the right direction, Mol Ther, 25, 2241, 10.1016/j.ymthe.2017.09.005 Majhail, 2009, Long-term survival and late relapse in 2-year survivors of autologous haematopoietic cell transplantation for Hodgkin and non-Hodgkin lymphoma, Br J Haematol, 147, 129, 10.1111/j.1365-2141.2009.07798.x Myers, 2018, Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large B-cell lymphoma, Cancer, 124, 816, 10.1002/cncr.31114 Maurer, 2014, Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy, J Clin Oncol, 32, 1066, 10.1200/JCO.2013.51.5866 Rigacci, 2012, Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study, Ann Hematol, 91, 931, 10.1007/s00277-011-1395-9 van Den Neste, 2017, Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study, Bone Marrow Transplant, 52, 216, 10.1038/bmt.2016.213 van Den Neste, 2016, Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the international CORAL study, Bone Marrow Transplant, 51, 51, 10.1038/bmt.2015.213 Van Kampen, 2011, Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry, J Clin Oncol, 29, 1342, 10.1200/JCO.2010.30.2596 Nastoupil, 2018, Axicabtagene ciloleucel (axi-cel) CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory large B-cell lymphoma: real world experience, Blood, 132, 91, 10.1182/blood-2018-99-114152